{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.2","upperLimit":"40.3","value":"5.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Time to AML transformation according to World Health Organization (WHO) Critieria","dispersionType":"Full Range","groups":[{"description":"All patients will be given their first dose of oral Ruxolitinib, 20 mg at first scheduled visit. After that dose and on all other days patients will self-administer oral Ruxolitinib at a dose of 40 mg daily divided into two equal doses approximately 12 hours apart. Patients will be treated for a total of 16 weeks. After treatment, patients will be followed monthly.\n\nRuxolitinib: Ruxolitinib 5 mg tablets, 4 per dose","id":"OG000","title":"Ruxolitinib"}],"paramType":"MEDIAN","populationDescription":"Participants who had AML transformation","reportingStatus":"POSTED","timeFrame":"Every 6 months after conclusion of treatment until end of study (40.3 months)","title":"Time to Acute Myeloid Leukemia (AML) Transformation","type":"SECONDARY","unitOfMeasure":"months"}